1573PWeekly epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma

ConclusionsEpirubicin has a modest clinical activity in pre-treated elderly patients with MPM in progression after one or two regimens, with an acceptable toxicity profile. It could be considered as a palliative treatment.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 17 July 2020Source: Respiratory Medicine Case ReportsAuthor(s): Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy, characterized by the classic pentad of haemolytic anemia, thrombocytopenia, fever, renal impairment, and neurological complications. Early identification of TTP is essential for instituting early treatment and improving survival. An extensive variety of drugs, including certain cytotoxic agents, have been reported to be associated with TTP [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Ihara H, Harada N, Shimada N, Kanamori K, Hayashi T, Uekusa T, Takahashi K Abstract A 64-year-old man with the bone marrow metastasis due to malignant pleural mesothelioma (MPM) was diagnosed with anemia, leukoerythroblastosis, thrombocytopenia, and lower back pain. A bone marrow biopsy demonstrated infiltrative malignant mesothelioma lesions in the bone marrow. The patient died within 15 days of the detection of the bone marrow involvement. Physicians should consider performing a bone marrow biopsy to diagnose bone marrow metastasis and treat patients with palliative chemotherapy at an earlier phase of th...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion This daily subcutaneous regimen of bortezomib showed a dose dependent plasma exposure, evidence of target inhibition and preliminary signs of clinical activity. However, cumulative neurological toxicity of this dose-dense daily regimen might preclude its further clinical development.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionThe combination treatment was well tolerated with manageable toxicities. The recommended phase II dose was 80  mg/m2/day for milciclib and 1000  mg/m2/day for gemcitabine. This combination treatment regimen showed encouraging clinical benefit in ~36% patients, including gemcitabine refractory patients. These results support further development of combination therapies with milciclib in advanced cancer patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
CONCLUSION: IMRT following EPP achieved excellent local control for MPM, that might lead to the long-term survival in selected patients. However, treatment burden including acute and late toxicities should be considered in this treatment approach. PMID: 28117611 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusions: The combination was well tolerated, the RP2D is 36mg/m2 ADI-PEG 20 weekly with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 3 weeks. Robust clinical activity has been observed with 78% pt having PR as best response on CT scan, as well as PR and SD in2 pt with sarcomatoid mesothelioma. The tolerability and response / disease control rate suggest that this combination may have clinical utility as first line treatment for these malignancies in ASS1-deficient pt. RP2D expansion cohorts are ongoing for pt with pleural mesothelioma or non-squamous NSCLC.Citation Format: Simon Pacey, James F. Spicer, Pui Ying Ch...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
Background: ATR mediates the homologous recombination DNA repair pathway and cellular response to replication stress. VX-970 is a potent and selective inhibitor of ATR (Ki
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Oral Presentations - Proffered Abstracts Source Type: research
Conclusions The initial safety profile of LY2090314 was established. MTD LY dose with pemetrexed/carboplatin is 40 mg IV every 3 weeks plus ranitidine. Efficacy of LY plus pemetrexed/carboplatin requires confirmation in randomized trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Asbestosis | Cancer & Oncology | Chemotherapy | Legislation | Liver | Mesothelioma | Palliative | Thrombocytopenia | Toxicology | Urology & Nephrology